These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Patrick AR; Avorn J; Choudhry NK Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Verhoef TI; Redekop WK; Veenstra DL; Thariani R; Beltman PA; van Schie RM; de Boer A; Maitland-van der Zee AH; Pharmacogenomics; 2013 Jun; 14(8):869-83. PubMed ID: 23746182 [TBL] [Abstract][Full Text] [Related]
5. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF; Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110 [TBL] [Abstract][Full Text] [Related]
6. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. You JH; Tsui KK; Wong RS; Cheng G Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807 [TBL] [Abstract][Full Text] [Related]
7. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. Schwartz JB; Kane L; Moore K; Wu AH J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231 [TBL] [Abstract][Full Text] [Related]
8. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel Hernandez-Suarez DF; Claudio-Campos K; Mirabal-Arroyo JE; Torres-Hernández BA; López-Candales A; Melin K; Duconge J J Investig Med High Impact Case Rep; 2016; 4(4):2324709616682049. PubMed ID: 28210634 [TBL] [Abstract][Full Text] [Related]
9. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Shin J; Kayser SR Pharmacotherapy; 2011 Sep; 31(9):863-70. PubMed ID: 21923587 [TBL] [Abstract][Full Text] [Related]
10. Use of genetic and nongenetic factors in warfarin dosing algorithms. Wu AH Pharmacogenomics; 2007 Jul; 8(7):851-61. PubMed ID: 18240910 [TBL] [Abstract][Full Text] [Related]
11. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. Stergiopoulos K; Brown DL JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Leey JA; McCabe S; Koch JA; Miles TP Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. You JH Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919 [TBL] [Abstract][Full Text] [Related]
14. [Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study]. Sychev DA; Antonov IM; Ignat'ev IV; Naumova IuV; Dmitriev VA; Kropacheva ES; Dobrovol'skiĭ OB; Panchenko EP; Tashenova IA; Kukes VG Kardiologiia; 2010; 50(5):42-6. PubMed ID: 20831047 [TBL] [Abstract][Full Text] [Related]
15. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Verhoef TI; Redekop WK; Darba J; Geitona M; Hughes DA; Siebert U; de Boer A; Maitland-van der Zee AH; Barallon R; Briz M; Daly A; Haschke-Becher E; Kamali F; Kirchheiner J; Manolopoulos VG; Pirmohamed M; Rosendaal FR; van Schie RM; Wadelius M; Pharmacogenomics; 2010 Jul; 11(7):989-1002. PubMed ID: 20602617 [TBL] [Abstract][Full Text] [Related]
16. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials. Tang T; Liu J; Zuo K; Cheng J; Chen L; Lu C; Han S; Xu J; Jia Z; Ye M; Pei E; Zhang X; Li M J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):387-94. PubMed ID: 25575537 [TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses. El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445 [TBL] [Abstract][Full Text] [Related]
19. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Li X; Yang J; Wang X; Xu Q; Zhang Y; Yin T Thromb Res; 2015 Apr; 135(4):621-9. PubMed ID: 25628141 [TBL] [Abstract][Full Text] [Related]